Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome

Clinical Genetics

Volumn 79, Issue 6, 2011, Pages 512-522

  Raskin, L ^a   Schwenter, F ^b   Freytsis, M ^c,d   Tischkowitz, M ^c,d   Wong, N ^d   Chong, G ^d,e   Narod, S A ^f   Levine, D A ^g   Bogomolniy, F ^g   Aronson, M ^b   Thibodeau, S N ^h   Hunt, K S ^h   Rennert, G ⁱ   Gallinger, S ^b   Gruber, S B ^a,j   Foulkes, W D ^c,d  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h MAYO CLINIC   (United States)

ⁱ CLALIT HEALTH SERVICES   (Israel)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

Ashkenazi Jews; Founder mutation; Lynch syndrome; MSH6

Indexed keywords

PROTEIN MSH6;

ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FOUNDER EFFECT; GENE MUTATION; GENETIC ANALYSIS; HAPLOTYPE; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; FOUNDER EFFECT; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INDEL MUTATION; JEWS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 79955607652     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2010.01594.x     Document Type: Article

References (34)

1. Vasen HF, Watson P, Mecklin JP et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999: 116 (6): 1453-1456.
2. Watson P, Riley B. The tumor spectrum in the Lynch syndrome. Fam Cancer 2005: 4 (3): 245-248.
3. Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 1994: 368 (6468): 258-261.
4. Fishel R, Lescoe MK, Rao MR et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993: 75 (5): 1027-1038.
5. Drummond JT, Li GM, Longley MJ et al. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science 1995: 268 (5219): 1909-1912.
6. Miyaki M, Konishi M, Tanaka K et al. Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer. Nat Genet 1997: 17 (3): 271-272.
7. Vilar E, Gruber SB. Microsatellite instability in colorectal cancer - the stable evidence. Nat Rev Clin Oncol 2010: 7 (3): 153-162.
8. Marsischky GT, Filosi N, Kane MF et al. Redundancy of Saccharomyces cerevisiae MSH3 and MSH6 in MSH2-dependent mismatch repair. Genes Dev 1996: 10 (4): 407-420.
9. Hendriks YM, Wagner A, Morreau H et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004: 127 (1): 17-25.
10. Plaschke J, Engel C, Krüger S et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol 2004: 22 (22): 4486-4494.
11. Hampel H, Frankel WL, Martin E et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol 2008: 26 (35): 5783-5788.
12. Hampel H, Frankel WL, Martin E et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005: 352 (18): 1851-1860.
13. Hampel H, Panescu J, Lockman J et al. Comment on: screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2007: 67 (19): 9603.
14. Baglietto L, Lindor NM, Dowty JG et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst 2009: 102 (3): 193-201.
15. Wagner A, Hendriks Y, Meijers-Heijboer EJ et al. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. J Med Genet 2001: 38 (5): 318-322.
16. Woods MO, Williams P, Careen A et al. A new variant database for mismatch repair genes associated with Lynch syndrome. Hum Mutat 2007: 28 (7): 669-673.
17. Goodfellow PJ, Buttin BM, Herzog TJ et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A 2003: 100 (10): 5908-5913.
18. Peterlongo P, Nafa K, Lerman GS et al. MSH6 germline mutations are rare in colorectal cancer families. Int J Cancer 2003: 107 (4): 571-579.
19. Hegde M, Blazo M, Chong B et al. Assay validation for identification of hereditary nonpolyposis colon cancer-causing mutations in mismatch repair genes MLH1, MSH2, and MSH6. J Mol Diagn 2005: 7 (4): 525-534.
20. Goldberg Y, Porat RM, Kedar I et al. An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC. Fam Cancer 2009: 9 (2): 141-150.
21. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998: 58 (22): 5248-5257.
22. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005: 76 (3): 449-462.
23. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001: 68 (4): 978-989.
24. Reeve JP, Rannala B. DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics 2002: 18 (6): 894-895.
25. Sun S, Greenwood CM, Thiffault I et al. The HNPCC associated MSH2*1906G→C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet 2005: 42 (10): 766-768.
26. Rothman KJ, Greenland S. Modern epidemiology, 2nd edn. Philadelphia, PA: Lippincott-Raven, 1998.
27. Wijnen J, de Leeuw W, Vasen H et al. Familial endometrial cancer in female carriers of MSH6 germline mutations. Nat Genet 1999: 23 (2): 142-144.
28. Greenwood CM, Sun S, Veenstra J et al. How old is this mutation? - A study of three Ashkenazi Jewish founder mutations. BMC Genet 2010: 11 (1): 39.
29. Roa BB, Boyd AA, Volcik K et al. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996: 14 (2): 185-187.
30. Niell BL, Long JC, Rennert G et al. Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. Am J Hum Genet 2003: 73 (6): 1250-1260.
31. Foulkes WD, Thiffault I, Gruber SB et al. The founder mutation MSH2*1906G→C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002: 71 (6): 1395-1412.
32. Lavie O, Gruber SB, Lejbkowicz F et al. Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation. Am J Obstet Gynecol 2008: 199 (2): 148e1-148e3.
33. Gruber SB, Ellis NA, Scott KK et al. BLM heterozygosity and the risk of colorectal cancer. Science 2002: 297 (5589): 2013.
34. Locker GY, Kaul K, Weinberg DS et al. The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 2006: 169 (1): 33-38.